CN104083328A - 包含2-氧代-1-吡咯烷衍生物的药物组合物 - Google Patents
包含2-氧代-1-吡咯烷衍生物的药物组合物 Download PDFInfo
- Publication number
- CN104083328A CN104083328A CN201410370728.3A CN201410370728A CN104083328A CN 104083328 A CN104083328 A CN 104083328A CN 201410370728 A CN201410370728 A CN 201410370728A CN 104083328 A CN104083328 A CN 104083328A
- Authority
- CN
- China
- Prior art keywords
- granule
- compositions
- weight
- cyclodextrin
- brivaracetam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
时间(小时) | 溶出的%布立西坦 |
0 | 0 |
0:15:00 | 101 |
0:30:00 | 101 |
0:45:00 | 102 |
1:00:00 | 102 |
量(mg) | C | D | E | F | G |
布立西坦 | 5.00 | 10.00 | 10.00 | 25.00 | 50.00 |
β环糊精 | 1.35 | 2.70 | 2.70 | 6.75 | 13.50 |
一水合乳糖 | 22.5 | 19.40 | 45.00 | 48.50 | 97.00 |
交联羧甲基纤维素钠 | 1.00 | 1.00 | 2.00 | 2.50 | 5.00 |
C | D | E | F | G | |
交联羧甲基纤维素钠 | 1.00 | 1.00 | 2.00 | 2.50 | 5.00 |
无水乳糖 | 22.55 | 19.30 | 45.10 | 48.25 | 96.50 |
硬脂酸镁 | 0.6 | 0.60 | 1.20 | 1.50 | 3.00 |
C | D | E | F | G | |
Opadry TM白 | 2.70 | 2.70 | 5.40 | 6.75 | 13.50 |
片芯质量(mg) | 54mg | 54mg | 108mg | 135mg | 270mg |
时间(min) | 0 | 5 | 30 | 45 |
平均值(%) | 0 | 88.1 | 100.6 | 101.6 |
时间(min) | 0 | 5 | 30 | 45 |
平均值(%) | 0 | 78.0 | 96.9 | 97.0 |
时间(min) | 0 | 10 | 30 | 45 |
平均值(%) | 0 | 100.1 | 99.8 | 101.0 |
时间(min) | 0 | 10 | 30 | 45 |
平均值(%) | 0 | 86.6 | 99.3 | 100.4 |
时间(min) | 0 | 15 | 30 | 45 |
平均值(%) | 0 | 100.0 | 100.7 | 99.8 |
量(mg) | H | I |
布立西坦 | 10.00 | 25.00 |
β环糊精 | 2.70 | 6.75 |
一水合乳糖 | 45.00 | 48.50 |
交联羧甲基纤维素钠 | 2.00 | 2.50 |
交联羧甲基纤维素钠 | 2.00 | 2.50 |
无水乳糖 | 45.10 | 48.25 |
硬脂酸镁 | 1.20 | 1.50 |
时间(min) | 0 | 15 | 30 | 45 |
平均值(%) | 0 | 101 | 101 | 101 |
时间(min) | 0 | 15 | 30 | 45 |
平均值(%) | 0 | 100.0 | 100.0 | 100.0 |
Claims (16)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09100083 | 2009-01-29 | ||
EP09100083.6 | 2009-01-29 | ||
CN201080005399.2A CN102292071B (zh) | 2009-01-29 | 2010-01-27 | 包含2-氧代-1-吡咯烷衍生物的药物组合物 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201080005399.2A Division CN102292071B (zh) | 2009-01-29 | 2010-01-27 | 包含2-氧代-1-吡咯烷衍生物的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104083328A true CN104083328A (zh) | 2014-10-08 |
CN104083328B CN104083328B (zh) | 2017-04-12 |
Family
ID=40622206
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410370728.3A Active CN104083328B (zh) | 2009-01-29 | 2010-01-27 | 包含2‑氧代‑1‑吡咯烷衍生物的药物组合物 |
CN201080005399.2A Active CN102292071B (zh) | 2009-01-29 | 2010-01-27 | 包含2-氧代-1-吡咯烷衍生物的药物组合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201080005399.2A Active CN102292071B (zh) | 2009-01-29 | 2010-01-27 | 包含2-氧代-1-吡咯烷衍生物的药物组合物 |
Country Status (23)
Country | Link |
---|---|
US (2) | US20120108464A1 (zh) |
EP (1) | EP2391349B1 (zh) |
JP (1) | JP5576401B2 (zh) |
KR (1) | KR101640164B1 (zh) |
CN (2) | CN104083328B (zh) |
AU (1) | AU2010215646B2 (zh) |
BR (1) | BRPI1007161B1 (zh) |
CA (1) | CA2747395C (zh) |
CY (1) | CY1115673T1 (zh) |
DK (1) | DK2391349T3 (zh) |
EA (1) | EA022057B1 (zh) |
ES (1) | ES2511047T3 (zh) |
HK (2) | HK1161988A1 (zh) |
HR (1) | HRP20141006T1 (zh) |
IL (1) | IL213545A (zh) |
ME (1) | ME01927B (zh) |
MX (1) | MX2011007267A (zh) |
PL (1) | PL2391349T3 (zh) |
PT (1) | PT2391349E (zh) |
RS (1) | RS53554B1 (zh) |
SI (1) | SI2391349T1 (zh) |
SM (1) | SMT201400155B (zh) |
WO (1) | WO2010094535A1 (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104800176A (zh) * | 2015-04-23 | 2015-07-29 | 广东赛烽医药科技有限公司 | 一种布瓦西坦口崩片及其制备方法 |
CN109833300A (zh) * | 2017-11-28 | 2019-06-04 | 浙江京新药业股份有限公司 | 一种抗癫痫药物口服组合物及其制备方法 |
CN110638743A (zh) * | 2019-10-25 | 2020-01-03 | 乐普制药科技有限公司 | 一种含布立西坦的组合物 |
CN113288872A (zh) * | 2020-02-21 | 2021-08-24 | 广东东阳光药业有限公司 | 一种2-吡咯烷酮衍生物的组合物及其制备方法 |
CN115192572A (zh) * | 2021-04-08 | 2022-10-18 | 成都同道慧宜生物医药科技有限公司 | 布立西坦药剂、其制备方法和应用 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102300562A (zh) * | 2009-01-29 | 2011-12-28 | Ucb医药有限公司 | 含有2-氧代-1-吡咯烷衍生物的药物组合物 |
US10973783B2 (en) | 2015-12-30 | 2021-04-13 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of seizure-related disorders |
US20190125725A1 (en) * | 2016-05-12 | 2019-05-02 | Jubilant Generics Limited | Pharmaceutical compositions comprising brivaracetam |
WO2019036713A1 (en) * | 2017-08-18 | 2019-02-21 | Abbvie Inc. | SOLID PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROIDS, POLYKYSTIC OVARY SYNDROME AND ADENOMYOSIS |
CA3097340A1 (en) | 2018-04-19 | 2019-10-24 | Abbvie Inc. | Methods of treating heavy menstrual bleeding |
CN112933059A (zh) * | 2021-03-25 | 2021-06-11 | 浙江昂利康制药股份有限公司 | 一种布立西坦片剂的干法制粒工艺 |
CN115721624A (zh) * | 2021-08-25 | 2023-03-03 | 北京海美源医药科技有限公司 | 一种布立西坦药物组合物及其制备方法和其应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5595761A (en) * | 1994-01-27 | 1997-01-21 | The Board Of Regents Of The University Of Oklahoma | Particulate support matrix for making a rapidly dissolving tablet |
CZ20032959A3 (cs) * | 2001-05-01 | 2004-01-14 | Pfizer Products Inc. | Způsob přípravy farmaceutické kompozice s nízkou dávkou léčiva mající rovnoměrnou distribuci a účinnost léčiva |
JP2005298338A (ja) | 2002-02-27 | 2005-10-27 | Eisai Co Ltd | 速崩壊性圧縮成形製剤 |
CN1186094C (zh) * | 2002-07-01 | 2005-01-26 | 蔡海德 | 具有促思维记忆功能的吡拉西坦药物组合物及其制备方法 |
WO2006099005A1 (en) * | 2005-03-09 | 2006-09-21 | Trustees Of Dartmouth College | Method for identifying agents which modulate gtpase activity involved in insulin-stimulated glut4 translocation |
EP1731149A1 (en) * | 2005-06-08 | 2006-12-13 | Ucb S.A. | Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy |
MX2007004294A (es) * | 2005-07-26 | 2008-03-11 | Ucb Pharma Sa | Composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion. |
ES2444009T3 (es) | 2006-06-08 | 2014-02-21 | Ucb Pharma, S.A. | Co-cristales de pirrolidinonas |
US20080069878A1 (en) * | 2006-08-31 | 2008-03-20 | Gopi Venkatesh | Drug Delivery Systems Comprising Solid Solutions of Weakly Basic Drugs |
US20080280862A1 (en) * | 2007-01-05 | 2008-11-13 | Cermak Jennifer M | Methods, compositions, and kits for the treatment of pain |
CN102300562A (zh) * | 2009-01-29 | 2011-12-28 | Ucb医药有限公司 | 含有2-氧代-1-吡咯烷衍生物的药物组合物 |
-
2010
- 2010-01-27 AU AU2010215646A patent/AU2010215646B2/en active Active
- 2010-01-27 US US13/142,869 patent/US20120108464A1/en not_active Abandoned
- 2010-01-27 KR KR1020117019926A patent/KR101640164B1/ko active IP Right Grant
- 2010-01-27 DK DK10701245.2T patent/DK2391349T3/da active
- 2010-01-27 WO PCT/EP2010/050892 patent/WO2010094535A1/en active Application Filing
- 2010-01-27 ES ES10701245.2T patent/ES2511047T3/es active Active
- 2010-01-27 ME MEP-2014-124A patent/ME01927B/me unknown
- 2010-01-27 US US13/146,074 patent/US10729653B2/en active Active
- 2010-01-27 JP JP2011546825A patent/JP5576401B2/ja active Active
- 2010-01-27 PL PL10701245T patent/PL2391349T3/pl unknown
- 2010-01-27 MX MX2011007267A patent/MX2011007267A/es active IP Right Grant
- 2010-01-27 RS RSP20140539 patent/RS53554B1/en unknown
- 2010-01-27 CA CA2747395A patent/CA2747395C/en active Active
- 2010-01-27 SI SI201030776T patent/SI2391349T1/sl unknown
- 2010-01-27 EP EP10701245.2A patent/EP2391349B1/en active Active
- 2010-01-27 EA EA201101116A patent/EA022057B1/ru unknown
- 2010-01-27 PT PT107012452T patent/PT2391349E/pt unknown
- 2010-01-27 CN CN201410370728.3A patent/CN104083328B/zh active Active
- 2010-01-27 CN CN201080005399.2A patent/CN102292071B/zh active Active
- 2010-01-27 BR BRPI1007161-0A patent/BRPI1007161B1/pt active IP Right Grant
-
2011
- 2011-06-14 IL IL213545A patent/IL213545A/en active IP Right Grant
-
2012
- 2012-03-14 HK HK12102566.6A patent/HK1161988A1/zh unknown
-
2014
- 2014-10-21 HR HRP20141006AT patent/HRP20141006T1/hr unknown
- 2014-10-23 SM SM201400155T patent/SMT201400155B/xx unknown
- 2014-10-23 CY CY20141100876T patent/CY1115673T1/el unknown
- 2014-11-21 HK HK14111804.7A patent/HK1198287A1/zh unknown
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104800176A (zh) * | 2015-04-23 | 2015-07-29 | 广东赛烽医药科技有限公司 | 一种布瓦西坦口崩片及其制备方法 |
CN109833300A (zh) * | 2017-11-28 | 2019-06-04 | 浙江京新药业股份有限公司 | 一种抗癫痫药物口服组合物及其制备方法 |
CN110638743A (zh) * | 2019-10-25 | 2020-01-03 | 乐普制药科技有限公司 | 一种含布立西坦的组合物 |
CN110638743B (zh) * | 2019-10-25 | 2023-03-28 | 乐普制药科技有限公司 | 一种含布立西坦的组合物 |
CN113288872A (zh) * | 2020-02-21 | 2021-08-24 | 广东东阳光药业有限公司 | 一种2-吡咯烷酮衍生物的组合物及其制备方法 |
CN115192572A (zh) * | 2021-04-08 | 2022-10-18 | 成都同道慧宜生物医药科技有限公司 | 布立西坦药剂、其制备方法和应用 |
CN115192572B (zh) * | 2021-04-08 | 2023-09-19 | 成都同道慧宜生物医药科技有限公司 | 布立西坦药剂、其制备方法和应用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104083328A (zh) | 包含2-氧代-1-吡咯烷衍生物的药物组合物 | |
KR101943686B1 (ko) | 구강내 붕괴정 및 그 제조 방법 | |
CN104906085A (zh) | 含有2-氧代-1-吡咯烷衍生物的药物组合物 | |
US8703203B2 (en) | Oral dosage form of deferasirox | |
CN102512393A (zh) | 一种托伐普坦的口腔崩解片 | |
CN109875972B (zh) | 一种奥美沙坦酯氨氯地平药物组合物 | |
JP2003034655A (ja) | 速崩壊性固形製剤 | |
CN103040780B (zh) | 快速崩解的普拉克索片剂药物组合物及其制备方法 | |
RU2613192C1 (ru) | Таблетки клозапина с пролонгированным высвобождением | |
JP2014037356A (ja) | カンデサルタンシレキセチル経口製剤 | |
CN101808630A (zh) | 阿利吉仑的盖仑制剂 | |
RU2674978C2 (ru) | Фармацевтическая композиция N-[5-[2-(3,5-диметоксифенил)этил]-2H-пиразол-3-ил]-4-[(3R,5S)-3,5-диметилпиперазин-1-ил]бензамида | |
RU2624229C2 (ru) | Таблетки клозапина с замедленным высвобождением и способ их получения | |
CN103006602B (zh) | 一种快速溶出的阿托伐他汀钙片及其制备方法 | |
SK50472005A3 (sk) | Tableta s obsahom valsartanu vyrobená priamym tabletovaním | |
EP2303239A1 (de) | Direktverpresste aliskiren-tabletten | |
Babu | FORMULATION AND EVALUATION AND STABILITY STUDIES OF BILAYER TABLETS OF METFORMIN AND LINAGLIPTIN | |
CN117338724A (zh) | 一种间苯三酚调释制剂及其制备方法 | |
CN108721233A (zh) | 一种左旋奥拉西坦口腔崩解制剂的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1198287 Country of ref document: HK |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160801 Address after: Brussels Applicant after: UCB PHARMA SA Address before: Brussels Applicant before: UCB Pharma SA |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1198287 Country of ref document: HK |